Literature DB >> 8306840

Colectomy in patients with inflammatory bowel disease and primary sclerosing cholangitis.

A B Post1, J M Bozdech, I Lavery, D S Barnes.   

Abstract

PURPOSE: The aim of this study was to assess risk factors for early postoperative death in patients with primary sclerosing cholangitis who are undergoing colectomy.
METHODS: The charts of 24 patients with primary sclerosing cholangitis who underwent colectomy between 1972 and 1990 at the Cleveland Clinic Foundation were reviewed. Clinical and laboratory data were collected and compiled to determine preoperative factors that might be helpful in predicting early postoperative death.
RESULTS: The only factor that predicted a poor outcome was cirrhosis at the time of surgery. Three of 8 patients with cirrhosis and 0 of 16 patients without cirrhosis had an early postoperative death (P < 0.05, Fisher's exact test).
CONCLUSION: We conclude that establishing whether or not patients with inflammatory bowel disease and primary sclerosing cholangitis have cirrhosis is helpful in determining the risk of colectomy.

Entities:  

Mesh:

Year:  1994        PMID: 8306840     DOI: 10.1007/BF02047543

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

Review 1.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

2.  Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy.

Authors:  Sombat Treeprasertsuk; Einar Björnsson; Emmanouil Sinakos; Emma Weeding; Keith D Lindor
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-08-06

Review 3.  Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and meta-analysis.

Authors:  John Ong; Michael F Bath; Carla Swift; Yasseen Al-Naeeb
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.